Etanercept, a tumour necrosis factor α receptor antagonist, and methotrexate in acute sensorineural hearing loss

Journal of Laryngology and Otology

Volumn 120, Issue 12, 2006, Pages 1064-1066

  Street, Ian ^a,b   Jobanputra, P ^a   Proofs, D W ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Autoimmune Diseases; Cochlea; Hearing Loss; Sensorineural

Indexed keywords

ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE DISEASE; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DISEASE DURATION; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; EMERGENCY CARE; FEMALE; HOSPITAL READMISSION; HUMAN; LABORATORY TEST; PERCEPTION DEAFNESS; RHEUMATOID ARTHRITIS; SOCIAL WORKER; TREATMENT FAILURE; TREATMENT OUTCOME;

AUTOIMMUNE DISEASES; FEMALE; HEARING LOSS, SENSORINEURAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 33846374683     PISSN: 00222151     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0022215106002593     Document Type: Article

References (8)

1. Broughton SS, Meyerhoff WE, Cohen SB. Immune-mediated inner ear disease: 10 year experience. Semin Arthritis Rheum 2004;34:544-8
2. Nair TS, Kozma KE, Hoefling NL, Kommareddi PK, Ueda Y, Gong T-W et al. Identification and characterisation of choline transporter-like protein 2, an inner ear glycoprotein of 68 and 70 kDa that is the target of antibody-induced hearing loss. J Neurosci 2004;24:1772-9
3. Gloddek B, Arnold W. Clinical and experimental studies of autoimmune inner ear disease. Acta Otolaryngol Suppl 2002;(548):10-14
4. Harris JP, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ et al. Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 2003;290:1875-83
5. Satoh H, Firestein GS, Billings PB, Harris JP, Keithley EM. Tumor necrosis factor-alpha, an initiator, and etanercept, an inhibitor of cochlear inflammation. Laryngoscope 2002;112:1627-34
6. Staecker H, Lefebvre PP. Autoimmune sensorineural hearing loss improved by tumor necrosis factor-alpha blockade: a case report. Acta Otolaryngol 2002;122:684-7
7. Matteson EL, Choi HK, Poe DS, Wise C, Lowe VJ, McDonald TJ et al. Etanercept for immune mediated cochleovestibular disorders: a multi-center, open-label pilot study. Arthritis Rheum (Arth Car Res) 2005;53:337-42
8. Klareskog L, van der Heijde D, de Jage JP, Gough A, Kalden J, Malaise M et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised trial. Lancet 2004;263:675-81